University of Notre Dame du Lac’s Nektar Therapeutics NKTR Stock Holding History

University of Notre Dame du Lac’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,039	Closed	-$2.04M	–	66
2019 Q1	$2.04M	Buy	4,039 +2	+0%	+$1.19K	0.45%	61
2018 Q4	$1.99M	Buy	+4,037	New	+$2.44M	0.48%	63
2018 Q3	–	Sell	-2,197	Closed	-$1.61M	–	76
2018 Q2	$1.61M	Sell	2,197 -6,824	-76%	-$7.87M	0.31%	65
2018 Q1	$14.4M	Buy	9,021 +4,608	+104%	+$5.94M	2.67%	5
2017 Q4	$3.95M	Sell	4,413 -4,371	-50%	-$2.59M	0.82%	48
2017 Q3	$3.16M	Buy	8,784 +475	+6%	+$149K	0.88%	53
2017 Q2	$2.44M	Sell	8,309 -3,379	-29%	-$976K	0.72%	64
2017 Q1	$4.12M	Buy	+11,688	New	+$2.63M	1.03%	49

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

University of Notre Dame du Lac's NKTR Position: Q2 2019 in Review

University of Notre Dame du Lac sold out of Nektar Therapeutics (NKTR) in Q2 2019, closing a stake of 4,039 shares — an estimated $2.04M sold.

University of Notre Dame du Lac first reported a position in NKTR in Q1 2017 and held it in 8 quarters. The position peaked at $14.4M in Q1 2018. 336 funds tracked by Wall St. Rank hold NKTR as of Q2 2019.

University of Notre Dame du Lac reported no remaining Nektar Therapeutics position as of Q2 2019 after selling out during the quarter.
University of Notre Dame du Lac sold 4,039 Nektar Therapeutics shares in Q2 2019, an estimated $2.04M.
University of Notre Dame du Lac first reported a position in Nektar Therapeutics in Q1 2017 and held it in 8 quarters.
University of Notre Dame du Lac's Nektar Therapeutics position peaked at $14.4M in Q1 2018.
336 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2019.

Based on University of Notre Dame du Lac's 13F filing for Q2 2019, filed 14 Aug 2019.